NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromboembolism (VTE). VTE is a significant concern among cancer patients, who are at heightened risks for developing as well as dying from the disease. The management of patients with cancer with VTE often requires multidisciplinary efforts at treating institutions. The NCCN panel comprises specialists from various fields: cardiology, hematology/hematologic oncology, internal medicine, interventional radiology, medical oncology, pharmacology/pharmacy, and surgery/surgical oncology. This article focuses on VTE prophylaxis for medical and surgical oncology inpatients and outpatients, and discusses risk factors for VTE development, risk assessment tools, as well as management methods, including pharmacological and mechanical prophylactics. Contraindications to therapeutic interventions and special dosing, when required, are also discussed.
Individual Disclosures for the NCCN Cancer-Associated Venous Thromboembolic Disease Panel
BlomJW, DoggenCJM, OsantoS, Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715–722.1570191310.1001/jama.293.6.715)| false
MulderFI, Horváth-PuhóE, van EsN, Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137:1959–1969.3317149410.1182/blood.2020007338)| false
KhoranaAA, DalalM, LinJ, et al.Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer2013;119:648–655.
KhoranaAA, DalalM, LinJ, Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013;119:648–655.2289359610.1002/cncr.27772)| false
KhoranaAA, FrancisCW, CulakovaE, et al.Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost2007;5:632–634.
KhoranaAA, FrancisCW, CulakovaE, Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632–634.10.1111/j.1538-7836.2007.02374.x17319909)| false
KhoranaAA, FrancisCW, CulakovaE, et al.Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer2007;110:2339–2346.
KhoranaAA, FrancisCW, CulakovaE, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339–2346.1791826610.1002/cncr.23062)| false
FotopoulouC, duBoisA, KaravasAN, et al.Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol2008;26:2683–2689.
FotopoulouC, duBoisA, KaravasAN, Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 2008;26:2683–2689.10.1200/JCO.2008.16.1109)| false
ChewHK, WunT, HarveyD, et al.Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med2006;166:458–464.
ChewHK, WunT, HarveyD, Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458–464.1650526710.1001/archinte.166.4.458)| false
ChewHK, WunT, HarveyDJ, Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70–76.1719490610.1200/JCO.2006.07.4393)| false
SørensenHT, MellemkjaerL, OlsenJH, Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–1850.10.1056/NEJM20001221343250411117976)| false
KudererNM, FrancisCW, CulakovaE, et al.Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy (abstract). J Clin Oncol2008;26(Supple 15):Abstract 9521.
AgnelliG, BolisG, CapussottiL, et al.A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg2006;243:89–95.
AgnelliG, BolisG, CapussottiL, A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89–95.1637174110.1097/01.sla.0000193959.44677.48)| false
OhashiY, IkedaM, KunitohH, et al.Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol2020;50:1246–1253.
OhashiY, IkedaM, KunitohH, Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol 2020;50:1246–1253.10.1093/jjco/hyaa11232715307)| false
KeyNS, KhoranaAA, KudererNM, et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol2020;38:496–520.
FargeD, BounameauxH, BrennerB, et al.International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol2016;17:e452–e466.
FargeD, BounameauxH, BrennerB, International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016;17:e452–e466.10.1016/S1470-2045(16)30369-227733271)| false
HeitJA, SilversteinMD, MohrDN, et al.Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med1999;159:445–453.
HeitJA, SilversteinMD, MohrDN, Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445–453.10.1001/archinte.159.5.44510074952)| false
AggarwalA, FullamL, BrownsteinAP, et al.Deep vein thrombosis (DVT) and pulmonary embolism (PE): awareness and prophylaxis practices reported by patients with cancer. Cancer Invest2015;33:405–410.
AggarwalA, FullamL, BrownsteinAP, Deep vein thrombosis (DVT) and pulmonary embolism (PE): awareness and prophylaxis practices reported by patients with cancer. Cancer Invest 2015;33:405–410.2618109610.3109/07357907.2015.1048871)| false
SecinFP, JibornT, BjartellAS, et al.Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol2008;53:134–145.
SecinFP, JibornT, BjartellAS, Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008;53:134–145.10.1016/j.eururo.2007.05.028)| false
GirardP, DecoususM, LaporteS, et al.Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med2001;164:1033–1037.
GirardP, DecoususM, LaporteS, Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med 2001;164:1033–1037.10.1164/ajrccm.164.6.210104511587992)| false
AndersonFA, Jr., WheelerHB, GoldbergRJ, et al.A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med1991;151:933–938.
AndersonFA, Jr., WheelerHB, GoldbergRJ, A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933–938.202514110.1001/archinte.1991.00400050081016)| false
KhoranaAA, KudererNM, CulakovaE, et al.Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood2008;111:4902–4907.
KhoranaAA, KudererNM, CulakovaE, Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902–4907.10.1182/blood-2007-10-11632718216292)| false
ChengYJ, LiuZH, YaoFJ, et al.Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med2013;10:e1001515.
ChengYJ, LiuZH, YaoFJ, Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med 2013;10:e1001515.2406889610.1371/journal.pmed.1001515)| false
EngaKF, BraekkanSK, Hansen-KroneIJ, et al.Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost2012;10:2068–2074.
EngaKF, BraekkanSK, Hansen-KroneIJ, Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost 2012;10:2068–2074.10.1111/j.1538-7836.2012.04880.x22882779)| false
HanssonPO, ErikssonH, WelinL, et al.Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: “the study of men born in 1913”. Arch Intern Med1999;159:1886–1890.
HanssonPO, ErikssonH, WelinL, Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: “the study of men born in 1913”. Arch Intern Med 1999;159:1886–1890.10.1001/archinte.159.16.1886)| false
Danin-MankowitzH, Ugarph-MorawskiA, BraunschweigF, et al.The risk of venous thromboembolism and physical activity level, especially high level: a systematic review. J Thromb Thrombolysis2021.
Danin-MankowitzH, Ugarph-MorawskiA, BraunschweigF, The risk of venous thromboembolism and physical activity level, especially high level: a systematic review. J Thromb Thrombolysis 2021.10.1007/s11239-020-02372-533389612)| false
van StralenKJ, DoggenCJ, LumleyT, et al.The relationship between exercise and risk of venous thrombosis in elderly people. J Am Geriatr Soc2008;56:517–522.
van StralenKJ, DoggenCJ, LumleyT, The relationship between exercise and risk of venous thrombosis in elderly people. J Am Geriatr Soc 2008;56:517–522.1817950010.1111/j.1532-5415.2007.01588.x)| false
MahmoodiBK, BrouwerJL, Ten KateMK, et al.A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost2010;8:1193–1200.
MahmoodiBK, BrouwerJL, Ten KateMK, A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost 2010;8:1193–1200.10.1111/j.1538-7836.2010.03840.x)| false
PoortSR, RosendaalFR, ReitsmaPH, et al.A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood1996;88:3698–3703.
PoortSR, RosendaalFR, ReitsmaPH, A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698–3703.10.1182/blood.V88.10.3698.bloodjournal88103698)| false
CerveraR, PietteJC, FontJ, et al.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002;46:1019–1027.
CerveraR, PietteJC, FontJ, Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–1027.10.1002/art.10187)| false
GinsburgKS, LiangMH, NewcomerL, et al.Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med1992;117:997–1002.
GinsburgKS, LiangMH, NewcomerL, Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997–1002.144398610.7326/0003-4819-117-12-997)| false
CukerA, ArepallyGM, ChongBH, et al.American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv2018;2:3360–3392.
CukerA, ArepallyGM, ChongBH, American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018;2:3360–3392.3048276810.1182/bloodadvances.2018024489)| false
SegalJB, StreiffMB, HofmannLV, et al.Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med2007;146:211–222.
SegalJB, StreiffMB, HofmannLV, Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007;146:211–222.10.7326/0003-4819-146-3-200702060-0015017261856)| false
MandalàM, BarniS, PrinsM, et al.Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol2010;21:871–876.
MandalàM, BarniS, PrinsM, Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010;21:871–876.10.1093/annonc/mdp35419713246)| false
MonrealM, FalgáC, ValleR, et al.Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med2006;119:1073–1079.
MonrealM, FalgáC, ValleR, Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006;119:1073–1079.1714525210.1016/j.amjmed.2006.04.028)| false
BørvikT, BrækkanSK, EngaK, COPD and risk of venous thromboembolism and mortality in a general population. Eur Respir J 2016;47:473–481.10.1183/13993003.00402-2015)| false
PiazzaG, GoldhaberSZ, KrollA, Venous thromboembolism in patients with chronic obstructive pulmonary disease. Am J Med 2012;125:1010–1018.10.1016/j.amjmed.2012.03.00722884176)| false
BertolettiL, QuenetS, LaporteS, et al.Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res2013;14:75.
BertolettiL, QuenetS, LaporteS, Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res 2013;14:75.2386576910.1186/1465-9921-14-75)| false
TangL, WuYY, LipGY, Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 2016;3:e30–e44.10.1016/S2352-3026(15)00228-826765646)| false
LeizoroviczA, TurpieAG, CohenAT, et al.Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost2005;3:28–34.
LeizoroviczA, TurpieAG, CohenAT, Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost 2005;3:28–34.1563426310.1111/j.1538-7836.2004.01094.x)| false
EliassonA, BergqvistD, BjörckM, et al.Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost2006;4:1897–1902.
EliassonA, BergqvistD, BjörckM, Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost 2006;4:1897–1902.1688193310.1111/j.1538-7836.2006.02152.x)| false
HongC, ZhuF, DuD, et al.Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis2005;183:169–174.
HongC, ZhuF, DuD, Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005;183:169–174.1593942410.1016/j.atherosclerosis.2005.03.047)| false
PrandoniP, BiloraF, MarchioriA, An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348:1435–1441.1268669910.1056/NEJMoa022157)| false
DarzeES, LatadoAL, GuimarãesAG, et al.Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest2005;128:2576–2580.
DarzeES, LatadoAL, GuimarãesAG, Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005;128:2576–2580.1623692610.1378/chest.128.4.2576)| false
KrögerK, WeilandD, OseC, Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297–303.10.1093/annonc/mdj06816282243)| false
PrandoniP, LensingAWA, PrinsMH, et al.Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med2002;137:955–960.
PrandoniP, LensingAWA, PrinsMH, Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955–960.1248471010.7326/0003-4819-137-12-200212170-00008)| false
PrandoniP, LensingAWA, PiccioliA, et al.Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002;100:3484–3488.
PrandoniP, LensingAWA, PiccioliA, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–3488.1239364710.1182/blood-2002-01-0108)| false
HeitJA, O’FallonWM, PettersonTM, et al.Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med2002;162:1245–1248.
HeitJA, O’FallonWM, PettersonTM, Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245–1248.1203894210.1001/archinte.162.11.1245)| false
BeamDM, CourtneyDM, KabrhelC, Risk of thromboembolism varies, depending on category of immobility in outpatients. Ann Emerg Med 2009;54:147–152.10.1016/j.annemergmed.2008.10.03319135280)| false
FlintermanLE, van Hylckama VliegA, RosendaalFR, et al.Body height, mobility, and risk of first and recurrent venous thrombosis. J Thromb Haemost2015;13:548–554.
FlintermanLE, van Hylckama VliegA, RosendaalFR, Body height, mobility, and risk of first and recurrent venous thrombosis. J Thromb Haemost 2015;13:548–554.2562796710.1111/jth.12860)| false
Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep2012;61:401–404.
Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep 2012;61:401–404.22672974)| false
LevitanN, DowlatiA, RemickSC, et al.Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore)1999;78:285–291.
LevitanN, DowlatiA, RemickSC, Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285–291.10.1097/00005792-199909000-00001)| false
OgrenM, BergqvistD, WåhlanderK, Trousseau’s syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95:541–545.1652558410.1160/TH05-10-0694)| false
SallahS, WanJY, NguyenNP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost2002;87:575–579.
SallahS, WanJY, NguyenNP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575–579.10.1055/s-0037-161305112008937)| false
HallIE, AndersenMS, KrumholzHM, et al.Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol2009;2009:182521–182521.
HallIE, AndersenMS, KrumholzHM, Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol 2009;2009:182521–182521.20445797)| false
MarrasLC, GeertsWH, PerryJR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer2000;89:640–646.
MarrasLC, GeertsWH, PerryJR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640–646.1093146410.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E)| false
KhoranaAA, FrancisCW, MenziesKE, et al.Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost2008;6:1983–1985.
KhoranaAA, FrancisCW, MenziesKE, Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008;6:1983–1985.10.1111/j.1538-7836.2008.03156.x18795992)| false
KhoranaAA, AhrendtSA, RyanCK, Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870–2875.1750498510.1158/1078-0432.CCR-06-2351)| false
AndtbackaRHI, BabieraG, SingletarySE, et al.Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg2006;243:96–101.
AndtbackaRHI, BabieraG, SingletarySE, Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 2006;243:96–101.10.1097/01.sla.0000193832.40178.0a16371742)| false
CarrierM, Le GalG, TayJ, et al.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost2011;9:653–663.
CarrierM, Le GalG, TayJ, Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011;9:653–663.10.1111/j.1538-7836.2011.04215.x)| false
De StefanoV, SoràF, RossiE, et al.The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost2005;3:1985–1992.
De StefanoV, SoràF, RossiE, The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005;3:1985–1992.10.1111/j.1538-7836.2005.01467.x16102104)| false
MohrenM, MarkmannI, Jentsch-UllrichK, et al.Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer2005;92:1349–1351.
MohrenM, MarkmannI, Jentsch-UllrichK, Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005;92:1349–1351.1579876710.1038/sj.bjc.6602504)| false
OttingerH, BelkaC, KozoleG, et al.Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin’s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol1995;54:186–194.
OttingerH, BelkaC, KozoleG, Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin’s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995;54:186–194.10.1111/j.1600-0609.1995.tb00214.x7720839)| false
HicksLK, CheungMC, DingK, et al.Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer2009;115:5516–5525.
HicksLK, CheungMC, DingK, Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 2009;115:5516–5525.10.1002/cncr.24596)| false
SandhuR, PanC-X, WunT, et al.The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer2010;116:2596–2603.
SandhuR, PanC-X, WunT, The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer 2010;116:2596–2603.20336780)| false
GadeIL, BraekkanSK, NaessIA, et al.The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost2017;15:1567–1575.
GadeIL, BraekkanSK, NaessIA, The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost 2017;15:1567–1575.10.1111/jth.1375228585779)| false
HammondJ, KozmaC, HartJC, Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol 2011;18:3240–3247.2158483710.1245/s10434-011-1723-2)| false
ToledanoTH, KondalD, KahnSR, The occurrence of venous thromboembolism in cancer patients following major surgery. Thromb Res 2013;131:e1–e5.2317462610.1016/j.thromres.2012.10.014)| false
BaarslagHJ, KoopmanMMW, HuttenBA, et al.Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med2004;15:503–507.
BaarslagHJ, KoopmanMMW, HuttenBA, Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004;15:503–507.1566808510.1016/j.ejim.2004.07.012)| false
HeitJA, SilversteinMD, MohrDN, et al.Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med2000;160:809–815.
HeitJA, SilversteinMD, MohrDN, Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–815.1073728010.1001/archinte.160.6.809)| false
LeeAY, LevineMN, ButlerG, et al.Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol2006;24:1404–1408.
GerberDE, SegalJB, LevyMY, et al.The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood2008;112:504–510.
GerberDE, SegalJB, LevyMY, The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008;112:504–510.1848042510.1182/blood-2007-10-117051)| false
VersoM, AgnelliG. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665–3675.10.1200/JCO.2003.08.00814512399)| false
van RoodenCJ, SchippersEF, BargeRMY, et al.Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol2005;23:2655–2660.
van RoodenCJ, SchippersEF, BargeRMY, Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005;23:2655–2660.10.1200/JCO.2005.05.002)| false
LordickF, HentrichM, DeckerT, et al.Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol2003;120:1073–1078.
LordickF, HentrichM, DeckerT, Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol 2003;120:1073–1078.10.1046/j.1365-2141.2003.04199.x12648081)| false
KhoranaAA, FrancisCW, CulakovaE, et al.Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer2005;104:2822–2829.
KhoranaAA, FrancisCW, CulakovaE, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822–2829.10.1002/cncr.21496)| false
OttenHM, MathijssenJ, ten CateH, et al.Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med2004;164:190–194.
OttenHM, MathijssenJ, ten CateH, Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004;164:190–194.1474484310.1001/archinte.164.2.190)| false
CummingsSR, EckertS, KruegerKA, et al.The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA1999;281:2189–2197.
CummingsSR, EckertS, KruegerKA, The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189–2197.1037657110.1001/jama.281.23.2189)| false
DecensiA, MaisonneuveP, RotmenszN, et al.Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation2005;111:650–656.
DecensiA, MaisonneuveP, RotmenszN, Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650–656.10.1161/01.CIR.0000154545.84124.AC)| false
FisherB, CostantinoJP, WickerhamDL, et al.Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005;97:1652–1662.
FisherB, CostantinoJP, WickerhamDL, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652–1662.10.1093/jnci/dji37216288118)| false
FisherB, CostantinoJP, WickerhamDL, et al.Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:1371–1388.
FisherB, CostantinoJP, WickerhamDL, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.974786810.1093/jnci/90.18.1371)| false
VogelVG, CostantinoJP, WickerhamDL, et al.Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila)2010;3:696–706.
VogelVG, CostantinoJP, WickerhamDL, Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696–706.10.1158/1940-6207.CAPR-10-0076)| false
LeafAN, PropertK, CorcoranC, et al.Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol2003;20:137–146.
LeafAN, PropertK, CorcoranC, Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol 2003;20:137–146.10.1385/MO:20:2:137)| false
AndersonGL, LimacherM, AssafAR, et al.Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA2004;291:1701–1712.
AndersonGL, LimacherM, AssafAR, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.10.1001/jama.291.14.170115082697)| false
RossouwJE, AndersonGL, PrenticeRL, et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA2002;288:321–333.
RossouwJE, AndersonGL, PrenticeRL, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.1211739710.1001/jama.288.3.321)| false
Blanco-MolinaA, Trujillo-SantosJ, TiradoR, et al.Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost2009;101:478–482.
Blanco-MolinaA, Trujillo-SantosJ, TiradoR, Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009;101:478–482.10.1160/TH08-10-068419277408)| false
LidegaardØ, NielsenLH, SkovlundCW, et al.Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ2011;343(oct25 4):d6423.
LidegaardØ, NielsenLH, SkovlundCW, Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343(oct25 4):d6423.2202739810.1136/bmj.d6423)| false
ManzoliL, De VitoC, MarzuilloC, Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012;35:191–205.22283630)| false
JickSS, HernandezRK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ2011;342(apr21 2):d2151.
JickSS, HernandezRK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342(apr21 2):d2151.10.1136/bmj.d215121511805)| false
ParkinL, SharplesK, HernandezRK, et al.Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ2011;342(apr21 2):d2139.
ParkinL, SharplesK, HernandezRK, Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342(apr21 2):d2139.10.1136/bmj.d2139)| false
TepperNK, DragomanMV, GaffieldME, et al.Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception2017;95:130–139.
El AccaouiRN, ShamseddeenWA, TaherAT. Thalidomide and thrombosis: a meta-analysis. Thromb Haemost 2007;97:1031–1036.1754930710.1160/TH06-09-0494)| false
WeberDM, ChenC, NiesvizkyR, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.1803276310.1056/NEJMoa070596)| false
ZangariM, SiegelE, BarlogieB, et al.Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood2002;100:1168–1171.
BennettCL, SilverSM, DjulbegovicB, et al.Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008;299:914–924.
BennettCL, SilverSM, DjulbegovicB, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–924.1831443410.1001/jama.299.8.914)| false
ConnollyGC, DalalM, LinJ, et al.Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer2012;78:253–258.
ConnollyGC, DalalM, LinJ, Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer 2012;78:253–258.10.1016/j.lungcan.2012.09.00723026639)| false
MandalaM, ClericiM, CorradinoI, et al.Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol2012;23:1416–1421.
MandalaM, ClericiM, CorradinoI, Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol 2012;23:1416–1421.10.1093/annonc/mdr52422052988)| false
MooreRA, AdelN, RiedelE, et al.High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol2011;29:3466–3473.
MooreRA, AdelN, RiedelE, High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011;29:3466–3473.10.1200/JCO.2011.35.566921810688)| false
KearneyJC, RossiS, GlinertK, et al.Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: a retrospective chart review validation of a VTE predictive model. [abstract]Blood2009;114:114. (Abstract 2503)
KearneyJC, RossiS, GlinertK, Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: a retrospective chart review validation of a VTE predictive model. [abstract]Blood 2009;114:114. (Abstract 2503)10.1182/blood.V114.22.2503.2503)| false
PriceLH, NguyenMB, PicozziVJ, et al.Portal vein thrombosis in pancreatic cancer: Natural history, risk factors, and implications for patient management [abstract]. Proceedings of the Gastrointestinal Cancers Symposium2010:Abstract 143.
PriceLH, NguyenMB, PicozziVJ, Portal vein thrombosis in pancreatic cancer: Natural history, risk factors, and implications for patient management [abstract]. Proceedings of the Gastrointestinal Cancers Symposium2010:Abstract 143.)| false
PabingerI, van EsN, HeinzeG, et al.A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol2018;5:e289–e298.
PabingerI, van EsN, HeinzeG, A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018;5:e289–e298.2988594010.1016/S2352-3026(18)30063-2)| false
VersoM, AgnelliG, BarniS, et al.A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med2012;7:291–292.
VersoM, AgnelliG, BarniS, A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 2012;7:291–292.10.1007/s11739-012-0784-y22547369)| false
PelzerU, SinnM, StielerJ, et al.[Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med Wochenschr2013;138:2084–2088.
PelzerU, SinnM, StielerJ, [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med Wochenschr 2013;138:2084–2088.24085361)| false
CellaCA, Di MinnoG, CarlomagnoC, Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV Study. Oncologist 2017;22:601–608.10.1634/theoncologist.2016-024628424324)| false
Muñoz MartínAJ, OrtegaI, FontC, et al.Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer2018;118:1056–1061.
Muñoz MartínAJ, OrtegaI, FontC, Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer 2018;118:1056–1061.10.1038/s41416-018-0027-829588512)| false
GerotziafasGT, TaherA, Abdel-RazeqH, et al.A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the Prospective COMPASS-Cancer-Associated Thrombosis study. Oncologist2017;22:1222–1231.
GerotziafasGT, TaherA, Abdel-RazeqH, A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the Prospective COMPASS-Cancer-Associated Thrombosis study. Oncologist 2017;22:1222–1231.2855003210.1634/theoncologist.2016-0414)| false
van EsN, Di NisioM, CesarmanG, et al.Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica2017;102:1494–1501.
van EsN, Di NisioM, CesarmanG, Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017;102:1494–1501.10.3324/haematol.2017.16906028550192)| false
KhoranaAA, SoffGA, KakkarAK, Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380:720–728.3078618610.1056/NEJMoa1814630)| false
CarrierM, Abou-NassarK, MallickR, Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;380:711–719.3051187910.1056/NEJMoa1814468)| false
GeertsWH, BergqvistD, PineoGF, et al.Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest2008;133:381S-453S.
GeertsWH, BergqvistD, PineoGF, Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.1857427110.1378/chest.08-0656)| false
KahnSR, MorrisonDR, DiendéréG, et al.Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism. Cochrane Database Syst Rev2018;4:CD008201.
KahnSR, MorrisonDR, DiendéréG, Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism. Cochrane Database Syst Rev 2018;4:CD008201.29687454)| false
KakkarVV, CorriganTP, FossardDP, et al.Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. Lancet1977;1:567–569.
KakkarVV, CorriganTP, FossardDP, Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. Lancet 1977;1:567–569.65660)| false
MismettiP, LaporteS, DarmonJY, et al.Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg2001;88:913–930.
MismettiP, LaporteS, DarmonJY, Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913–930.10.1046/j.0007-1323.2001.01800.x11442521)| false
AgnelliG, BergqvistD, CohenAT, et al.Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg2005;92:1212–1220.
KakkarAK, LevineM, PinedoHM, Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003;8:381–388.1289733510.1634/theoncologist.8-4-381)| false
CohenAT, TapsonVF, BergmannJF, et al.Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet2008;371:387–394.
CohenAT, TapsonVF, BergmannJF, Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387–394.1824241210.1016/S0140-6736(08)60202-0)| false
TapsonVF, DecoususH, PiniM, et al.Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest2007;132:936–945.
TapsonVF, DecoususH, PiniM, Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936–945.10.1378/chest.06-299317573514)| false
CoubanS, GoodyearM, BurnellM, et al.Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol2005;23:4063–4069.
CoubanS, GoodyearM, BurnellM, Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063–4069.1576763910.1200/JCO.2005.10.192)| false
KarthausM, KretzschmarA, KröningH, et al.Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol2006;17:289–296.
KarthausM, KretzschmarA, KröningH, Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289–296.1631701210.1093/annonc/mdj059)| false
VersoM, AgnelliG, BertoglioS, et al.Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol2005;23:4057–4062.
VersoM, AgnelliG, BertoglioS, Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057–4062.10.1200/JCO.2005.06.08415767643)| false
YoungAM, BillinghamLJ, BegumG, et al.Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet2009;373:567–574.
YoungAM, BillinghamLJ, BegumG, Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009;373:567–574.1921799110.1016/S0140-6736(09)60205-1)| false
SpyropoulosAC, AndersonFA, Jr., FitzGeraldG, et al.Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest2011;140:706–714.
SpyropoulosAC, AndersonFA, Jr., FitzGeraldG, Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011;140:706–714.10.1378/chest.10-194421436241)| false
GrantPJ, GreeneMT, ChopraV, et al.Assessing the Caprini score for risk assessment of venous thromboembolism in hospitalized medical patients. Am J Med2016;129:528–535.
GrantPJ, GreeneMT, ChopraV, Assessing the Caprini score for risk assessment of venous thromboembolism in hospitalized medical patients. Am J Med 2016;129:528–535.2655197710.1016/j.amjmed.2015.10.027)| false
BarbarS, NoventaF, RossettoV, et al.A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost2010;8:2450–2457.
BarbarS, NoventaF, RossettoV, A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010;8:2450–2457.2073876510.1111/j.1538-7836.2010.04044.x)| false
GreeneMT, SpyropoulosAC, ChopraV, et al.Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med2016;129:1001.e1009–1001.e1018.
GreeneMT, SpyropoulosAC, ChopraV, Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med 2016;129:1001.e1009–1001.e1018.10.1016/j.amjmed.2016.03.031)| false
KucherN, LeizoroviczA, VaitkusPT, et al.Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med2005;165:341–345.
KucherN, LeizoroviczA, VaitkusPT, Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005;165:341–345.10.1001/archinte.165.3.341)| false
LeizoroviczA, CohenAT, TurpieAG, et al.Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation2004;110:874–879.
LeizoroviczA, CohenAT, TurpieAG, Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874–879.1528936810.1161/01.CIR.0000138928.83266.24)| false
SamamaMM, CohenAT, DarmonJY, et al.A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med1999;341:793–800.
SamamaMM, CohenAT, DarmonJY, A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793–800.1047777710.1056/NEJM199909093411103)| false
LederleFA, SacksJM, FioreL, The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 2006;119:54–59.1643118510.1016/j.amjmed.2005.03.049)| false
KakkarAK, CimminielloC, GoldhaberSZ, Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011;365:2463–2472.10.1056/NEJMoa111128822204723)| false
KahnSR, LimW, DunnAS, et al.Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141:e195S–226S.
KahnSR, LimW, DunnAS, Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e195S–226S.10.1378/chest.11-229622315261)| false
CohenAT, DavidsonBL, GallusAS, et al.Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ2006;332:325–329.
CohenAT, DavidsonBL, GallusAS, Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325–329.1643937010.1136/bmj.38733.466748.7C)| false
BelchJJ, LoweGD, WardAG, Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115–117.729197110.1177/003693308102600205)| false
DentaliF, DouketisJD, GianniM, et al.Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med2007;146:278–288.
DentaliF, DouketisJD, GianniM, Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278–288.1731005210.7326/0003-4819-146-4-200702200-00007)| false
ClagettGP, ReischJS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227–240.10.1097/00000658-198808000-000162456748)| false
KingCS, HolleyAB, JacksonJL, et al.Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest2007;131:507–516.
KingCS, HolleyAB, JacksonJL, Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest 2007;131:507–516.10.1378/chest.06-186117296655)| false
GruberUF, DuckertF, FridrichR, et al.Prevention of postoperative thromboembolism by dextran 40, low doses of heparin, or xantinol nicotinate. Lancet1977;1:207–210.
GruberUF, DuckertF, FridrichR, Prevention of postoperative thromboembolism by dextran 40, low doses of heparin, or xantinol nicotinate. Lancet 1977;1:207–210.10.1016/S0140-6736(77)91011-X)| false
RasmussenMS, JorgensenLN, Wille-JørgensenP, et al.Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost2006;4:2384–2390.
RasmussenMS, JorgensenLN, Wille-JørgensenP, Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006;4:2384–2390.1688193410.1111/j.1538-7836.2006.02153.x)| false
BergqvistD, AgnelliG, CohenAT, et al.Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med2002;346:975–980.
BergqvistD, AgnelliG, CohenAT, Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–980.1191930610.1056/NEJMoa012385)| false
TurpieAG, BauerKA, CapriniJA, et al.Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost2007;5:1854–1861.
KakkarVV, BoecklO, BoneuB, et al.Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg1997;21:2–8., discussion 8–9.
KakkarVV, BoecklO, BoneuB, Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg 1997;21:2–8., discussion 8–9.894317010.1007/s002689900185)| false
KoppenhagenK, AdolfJ, MatthesM, et al.Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost1992;67:627–630.
McLeodRS, GeertsWH, SnidermanKW, et al.Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg2001;233:438–444.
McLeodRS, GeertsWH, SnidermanKW, Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001;233:438–444.1122463410.1097/00000658-200103000-00020)| false
ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg1997;84:1099–1103.
ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099–1103.9278651)| false
GuntupalliSR, BrenneckeA, BehbakhtK, et al.Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open2020;3:e207410.
GuntupalliSR, BrenneckeA, BehbakhtK, Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 2020;3:e207410.3258923010.1001/jamanetworkopen.2020.7410)| false
McGowanKE, MakariJ, DiamantourosA, et al.Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program. Blood2016;127:1954–1959.
McGowanKE, MakariJ, DiamantourosA, Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program. Blood 2016;127:1954–1959.10.1182/blood-2015-07-66000126817956)| false
AklEA, TerrenatoI, BarbaM, et al.Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med2008;168:1261–1269.
AklEA, TerrenatoI, BarbaM, Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008;168:1261–1269.1857408210.1001/archinte.168.12.1261)| false
DeBernardoRL, Jr., PerkinsRB, LittellRD, et al.Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol2005;105:1006–1011.
NutescuEA, SpinlerSA, WittkowskyA, et al.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother2009;43:1064–1083.
NutescuEA, SpinlerSA, WittkowskyA, Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43:1064–1083.10.1345/aph.1L19419458109)| false
BeckerRC, SpencerFA, GibsonM, et al.Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J2002;143:753–759.
BeckerRC, SpencerFA, GibsonM, Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753–759.1204033410.1067/mhj.2002.120774)| false
BazinetA, AlmanricK, BrunetC, Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005;116:41–50.10.1016/j.thromres.2004.10.00415850607)| false
ChowSL, ZammitK, WestK, et al.Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol2003;43:586–590.
ChowSL, ZammitK, WestK, Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003;43:586–590.10.1177/009127000325342012817521)| false
ShprecherAR, Cheng-LaiA, MadsenEM, et al.Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy2005;25:817–822.
ShprecherAR, Cheng-LaiA, MadsenEM, Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 2005;25:817–822.10.1592/phco.2005.25.6.81715927900)| false
LimW, DentaliF, EikelboomJW, et al.Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med2006;144:673–684.
LimW, DentaliF, EikelboomJW, Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673–684.10.7326/0003-4819-144-9-200605020-0001116670137)| false
SpinlerSA, InversoSM, CohenM, et al.Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J2003;146:33–41.
SpinlerSA, InversoSM, CohenM, Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33–41.10.1016/S0002-8703(03)00121-212851605)| false
ThorevskaN, Amoateng-AdjepongY, SabahiR, et al.Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest2004;125:856–863.
ThorevskaN, Amoateng-AdjepongY, SabahiR, Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004;125:856–863.1500694210.1378/chest.125.3.856)| false
ColletJP, MontalescotG, AgnelliG, et al.Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J2005;26:2285–2293.
ColletJP, MontalescotG, AgnelliG, Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005;26:2285–2293.10.1093/eurheartj/ehi337)| false
FoxKA, BassandJP, MehtaSR, et al.Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med2007;147:304–310.
FoxKA, BassandJP, MehtaSR, Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007;147:304–310.1778548510.7326/0003-4819-147-5-200709040-00005)| false
ScholtenDJ, HoedemaRM, ScholtenSE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg2002;12:19–24.
ScholtenDJ, HoedemaRM, ScholtenSE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002;12:19–24.1186829110.1381/096089202321144522)| false
SimoneEP, MadanAK, TichanskyDS, et al.Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc2008;22:2392–2395.
FrederiksenSG, HedenbroJL, NorgrenL. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg2003;90:547–548.
FrederiksenSG, HedenbroJL, NorgrenL. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003;90:547–548.10.1002/bjs.406812734859)| false
MartinezL, BurnettA, BorregoM, et al.Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health Syst Pharm2011;68:1716–1722.
MartinezL, BurnettA, BorregoM, Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. Am J Health Syst Pharm 2011;68:1716–1722.2188088710.2146/ajhp110010)| false
KleinW, BuchwaldA, HillisSE, et al.Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: fragmin in unstable coronary artery disease study (FRIC). Circulation1997;96:61–68.
KleinW, BuchwaldA, HillisSE, Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61–68.923641810.1161/01.CIR.96.1.61)| false
GaboritB, MoulinPA, BegeT, et al.Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. Pharmacol Res2018;131:211–217.
GaboritB, MoulinPA, BegeT, Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. Pharmacol Res 2018;131:211–217.2945229010.1016/j.phrs.2018.02.012)| false
KardysCM, StonerMC, ManwaringML, et al.Safety and efficacy of intravascular ultrasound-guided inferior vena cava filter in super obese bariatric patients. Surg Obes Relat Dis2008;4:50–54.
SteibA, DegirmenciSE, JunkeE, et al.Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surg Obes Relat Dis2016;12:613–621.
SteibA, DegirmenciSE, JunkeE, Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surg Obes Relat Dis 2016;12:613–621.10.1016/j.soard.2015.08.50526686309)| false
BrunettiL, WassefA, SadekR, et al.Anticoagulant activity of enoxaparin and unfractionated heparin for venous thromboembolism prophylaxis in obese patients undergoing sleeve gastrectomy. Surg Obes Relat Dis2019;15:363–373.
CelikF, HuitemaAD, HooijbergJH, et al.Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. Obes Surg2015;25:628–634.
CelikF, HuitemaAD, HooijbergJH, Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. Obes Surg 2015;25:628–634.2522387110.1007/s11695-014-1435-3)| false
SinghK, PodolskyER, UmS, et al.Evaluating the safety and efficacy of BMI-based preoperative administration of low-molecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg2012;22:47–51.
RondinaMT, WheelerM, RodgersGM, et al.Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res2010;125:220–223.
RondinaMT, WheelerM, RodgersGM, Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010;125:220–223.10.1016/j.thromres.2009.02.00319272635)| false
Al OtaibN, BootahZ, Al AmmariMA, et al.Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients. Ann Thorac Med2017;12:199–203.
Al OtaibN, BootahZ, Al AmmariMA, Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients. Ann Thorac Med 2017;12:199–203.10.4103/atm.ATM_31_1728808492)| false
FreemanA, HornerT, PendletonRC, et al.Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol2012;87:740–743.
FreemanA, HornerT, PendletonRC, Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 2012;87:740–743.2256558910.1002/ajh.23228)| false
SteeleKE, CannerJ, ProkopowiczG, et al.The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surg Obes Relat Dis2015;11:672–683.
SteeleKE, CannerJ, ProkopowiczG, The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Surg Obes Relat Dis 2015;11:672–683.2562043610.1016/j.soard.2014.10.003)| false
Clarke-PearsonDL, SynanIS, DodgeR, et al.A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol1993;168:1146–1153., discussion 1153–1154.
Clarke-PearsonDL, SynanIS, DodgeR, A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146–1153., discussion 1153–1154.10.1016/0002-9378(93)90360-U8475960)| false
RamirezJI, VassiliuP, Gonzalez-RuizC, et al.Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg2003;69:941–945.
RamirezJI, VassiliuP, Gonzalez-RuizC, Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg 2003;69:941–945.14627252)| false
DennisM, SandercockP, ReidJ, et al.Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet2013;382:516–524.
DennisM, SandercockP, ReidJ, Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 2013;382:516–524.2372716310.1016/S0140-6736(13)61050-8)| false
DennisM, SandercockPA, ReidJ, et al.Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet2009;373:1958–1965.
DennisM, SandercockPA, ReidJ, Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009;373:1958–1965.10.1016/S0140-6736(09)60941-719477503)| false
MartinoMA, BorgesE, WilliamsonE, Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 2006;107:666–671.10.1097/01.AOG.0000200046.28199.ae16507939)| false
CohenAT, SkinnerJA, WarwickD, et al.The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br2007;89:887–892.
CohenAT, SkinnerJA, WarwickD, The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br 2007;89:887–892.10.1302/0301-620X.89B7.18556)| false
SpencerFA, LessardD, EmeryC, Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167:1471–1475.10.1001/archinte.167.14.147117646600)| false
MaraveyasA, WatersJ, RoyR, et al.Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer2012;48:1283–1292.
MaraveyasA, WatersJ, RoyR, Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012;48:1283–1292.2210090610.1016/j.ejca.2011.10.017)| false
PelzerU, OpitzB, DeutschinoffG, et al.Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol2015;33:2028–2034.
GouldMK, GarciaDA, WrenSM, et al.Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest2012;141:e227S–277S.
GouldMK, GarciaDA, WrenSM, Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e227S–277S.2231526310.1378/chest.11-2297)| false
FelderS, RasmussenMS, KingR, et al.Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev2019;8:CD004318.
FelderS, RasmussenMS, KingR, Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2019;8:CD004318.)| false
NapolitanoM, SacculloG, MariettaM, et al.Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus2019;17:171–180.
NapolitanoM, SacculloG, MariettaM, Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus 2019;17:171–180.30418130)| false
